J&J, Teva offer a massive $48B combined to wrap opioid suits, but not all plaintiffs are on board With reports like that in the ether, it’s no wonder some plaintiffs are reticent to sign on to the “framework deal” that includes the Teva and J&J offers, along with additional deals with three drug distributors. Officials in at least four states have pushed back against the proposal, arguing that Teva’s agreement is “overvalued to make the settlement look better,” Hunter Shkolnik, a lawyer on a plaintiffs executive committee, told Reuters. Télécharger